Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ophthalmology

Free Subscription Articles published in Lancet Retrieve available abstracts of 31 articles: HTML format

Single Articles

March 2024
1. CAMPOCHIARO PA, Avery R, Brown DM, Heier JS, et al
   Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.
   Lancet. 2024 Mar 27:S0140-6736(24)00310-6. doi: 10.1016/S0140-6736(24)00310.
   PubMed     Abstract available
   
   
   
2. RAKOCZY EP
   The promise of long-term treatment for neovascular age-related macular degeneration.
   Lancet. 2024 Mar 27:S0140-6736(24)00428-8. doi: 10.1016/S0140-6736(24)00428.
   PubMed    
   
   
   
3. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
   Behcet's syndrome.
   Lancet. 2024;403:1093-1108.
   PubMed     Abstract available
   
   
   
4. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
   Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
   Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
   PubMed     Abstract available
   
   
   
5. LANZETTA P, Korobelnik JF, Heier JS, Leal S, et al
   Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
   Lancet. 2024 Mar 7:S0140-6736(24)00063-1. doi: 10.1016/S0140-6736(24)00063.
   PubMed     Abstract available
   
   
   
6. CHEW EY
   Increasing concentrations of intravitreal therapies for neovascular age-related macular degeneration.
   Lancet. 2024 Mar 7:S0140-6736(24)00229-0. doi: 10.1016/S0140-6736(24)00229.
   PubMed    
   
   
   
7. GABRIELLE PH, Creuzot-Garcher C
   Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
   Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
   PubMed    
   
   
   January 2024
8. CYPERS G, Tsitsi P
   Retinitis pigmentosa and pes cavus in PHARC-polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract-syndrome in a 62-year-old man.
   Lancet. 2024;403:391.
   PubMed    
   
   
   
9. SPEKREIJSE L, van den Biggelaar F, Nuijts R
   Equity, access, and carbon cost-effectiveness of bilateral cataract surgery - Authors' reply.
   Lancet. 2024;403:354.
   PubMed    
   
   
   
10. LIN JC, Greenberg PB
    Equity, access, and carbon cost-effectiveness of bilateral cataract surgery.
    Lancet. 2024;403:353.
    PubMed    
    
    
    
11. TING DSJ, Buchan JC
    Equity, access, and carbon cost-effectiveness of bilateral cataract surgery.
    Lancet. 2024;403:353-354.
    PubMed    
    
    
    
12. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    PubMed     Abstract available
    
    
    October 2023
13. HEIER JS, Lad EM, Holz FG, Rosenfeld PJ, et al
    Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
    Lancet. 2023;402:1434-1448.
    PubMed     Abstract available
    
    
    
14. CHEW EY
    Complement inhibitors for the treatment of geographic atrophy.
    Lancet. 2023;402:1396-1398.
    PubMed    
    
    
    September 2023
15. JAYARAM H, Kolko M, Friedman DS, Gazzard G, et al
    Glaucoma: now and beyond.
    Lancet. 2023 Sep 21:S0140-6736(23)01289-8. doi: 10.1016/S0140-6736(23)01289.
    PubMed     Abstract available
    
    
    June 2023
16. PETRUSHKIN H, Solebo AL
    Imaging inflammation in early-onset sarcoidosis: granulomatous anterior uveitis in a 7-year-old girl.
    Lancet. 2023;401:1963.
    PubMed    
    
    
    May 2023
17. DMUCHOWSKA DA, Obuchowska I, Konopinska J
    Immediate versus delayed sequential bilateral cataract surgery.
    Lancet. 2023 May 15:S0140-6736(23)00692-X. doi: 10.1016/S0140-6736(23)00692.
    PubMed    
    
    
    
18. SPEKREIJSE L, Simons R, Winkens B, van den Biggelaar F, et al
    Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
    Lancet. 2023 May 15:S0140-6736(23)00525-1. doi: 10.1016/S0140-6736(23)00525.
    PubMed     Abstract available
    
    
    
19. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    PubMed     Abstract available
    
    
    March 2023
20. GUYMER RH, Campbell TG
    Age-related macular degeneration.
    Lancet. 2023 Mar 27:S0140-6736(22)02609-5. doi: 10.1016/S0140-6736(22)02609.
    PubMed     Abstract available
    
    
    December 2022
21. CICINELLI MV, Buchan JC, Nicholson M, Varadaraj V, et al
    Cataracts.
    Lancet. 2022 Dec 21:S0140-6736(22)01839-6. doi: 10.1016/S0140-6736(22)01839.
    PubMed     Abstract available
    
    
    September 2022
22. BOWMAN SJ, Dorner T, Mariette X, Luo WL, et al
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials? - Authors' reply.
    Lancet. 2022;400:808-809.
    PubMed    
    
    
    
23. DYBALL S, Parker B, Bruce IN
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials?
    Lancet. 2022;400:807-808.
    PubMed    
    
    
    August 2022
24. BAGENAL J, Khanna R, Hawkes S
    Not misogynistic but myopic: the new women's health strategy in England.
    Lancet. 2022 Aug 10. pii: S0140-6736(22)01486.
    PubMed    
    
    
    January 2022
25. WYKOFF CC, Abreu F, Adamis AP, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00018.
    PubMed     Abstract available
    
    
    
26. HEIER JS, Khanani AM, Quezada Ruiz C, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00010.
    PubMed     Abstract available
    
    
    
27. CHIA MA, Keane PA
    Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00105.
    PubMed    
    
    
    
28. SARAUX A, Devauchelle-Pensec V
    Primary Sjogren's syndrome: new beginning for evidence-based trials.
    Lancet. 2022;399:121-122.
    PubMed    
    
    
    
29. BOWMAN SJ, Fox R, Dorner T, Mariette X, et al
    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Lancet. 2022;399:161-171.
    PubMed     Abstract available
    
    
    
30. KAMOI K, Uchimaru K, Tojo A, Watanabe T, et al
    HTLV-1 uveitis and Graves' disease presenting with sudden onset of blurred vision.
    Lancet. 2022;399:60.
    PubMed    
    
    
    October 2021
31. AYADI K, Gallaoui S, Ben Nsir A
    Pituitary apoplexy, but not as we thought: a xanthogranuloma rather than an adenoma.
    Lancet. 2021;398:e16.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ophthalmology is free of charge.